Vindas PJ, Segura VY, Ureña GS, Rojas UL

Language: Spanish
References: 23
Page: 55-63
PDF size: 639.49 Kb.

ABSTRACT

Currently, Hypertrophic Cardiomyopathy (HCM) is one of the most common hereditary cardiac conditions. It is defined as a cardiac muscle disorder inherited as an autosomal dominant disease with variable expression, caused by mutations in one of several sarcomere genes leading to an unexplained and abnormal left ventricular (LV) thickening usually asymmetrical, that lacks chamber dilation and it is linked to myocyte disarray and fibrosis. Diagnostic assessment of HMC is most often made via echocardiographic evaluation identifying the left ventricular hypertrophy (LVH), estimating changes in the left ventricular outflow tract gradients, systolic and diastolic performance, and mitral valve (MV) structure and function. In terms of management’s strategies, surgical myectomy, alcohol septal ablation or radiofrequency septal ablation are used for attenuating outflow obstruction and symptoms of heart failure, the placement of an implantable defibrillator to prevent sudden death and the use of drugs to control and prevent atrial fibrillation and stroke.

REFERENCES

1. Teare D. Asymmetrical hypertrophy of the heart in young adults. Br Heart J. 1958; 20(1): 1-8.

2. Elliott P, Anastasakis A, Borger M, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014; 35:2733.

3. Gersh B, Maron B, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg. 2011; 142:e153-203.

4. Zipes D, Libby P, Bonow R, Mann D, Tomaselli G. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. Oxford. UK: Elsevier. 11th Edition, 2018; 1602-1615.

5. Maron B, Maron M. Hypertrophic cardiomyopathy. Lancet. 2013; 381: 242-255.

6. Geske J, Ommen S, Gersh B. Hypertrophic cardiomyopathy: Clinical Update. JACC Heart Fail. 2018; 6: 364-375.

7. Maron B, Rown E, Maron M. Global Burden of Hypertrophic Cardiomyopathy. JACC Heart Fail. 2018; 6(5):376-378.

8. McKenna W, Maron B, Thiene G. Classification, Epidemiology and Global Burden of Cardiomyopathies. Circ Res. 2017; 121(7): 722-730.

9. Marian A, Braunwald E. Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis and Therapy. Circ Res. 2017; 121(7): 749-770.

10. Prondzynski M, Mearini G, Carrier L. Gene therapy strategies in the treatment of hypertrophic cardiomyopathy. Pflugers Arch Eur J Physiol. 2018; 1-9.

11. Liew A, Vassiliou V, Cooper R, Raphael C. Hypertrophic Cardiomyopathy Past, Present and Future. J Clin Med. 2017; 6(12).

12. Santos J, Sabater M, Gimeno J. Hypertrophic cardiomyopathy. Med Clin (Barc). 2018; 150(11): 434-442.

13. Veselka J, Anavekar N, Charron P. Hypertrophic Obstructive Cardiomyopathy. Lancet. 2017; 389(10075): 1253-1267.

14. Maron B. Clinical Course and Management of Hypertrophic Cardiomyopathy. New England Journal of Medicine. 2018; 7779(7): 655-668.

15. Argulian E, Sherrid M, Messerli F. Misconceptions and Facts about Hypertrophic Cardiomyopathy. The American Journal of Medicine. 2016; 129(2): 148- 152.

16. Cao Y, Zhang P. Review of recent advances en the management of hypertrophic cardiomyopathy. Eur Rev Med Pharmacol Sci. 2017; 21(22): 5207-5210.

17. Nishimura R, Seggewiss H, Schaff H. Hypertrophic Obstructive Cardiomyopathy Surgical Myectomy and Septal Ablation. Circ Res. 2017; 121(7): 771-783.

18. Maekawa Y, Akita K, Takanashi S. Contemporary Septal Reduction Therapy in Drug Refractory Hypertrophic Obstructive Cardiomyopathy. Circ J. 2018; 82(8): 1977-1984.

19. Price J et al. Hypertrophic obstructive cardiomyopathy: review of surgical treatment. Asian Cardiovasc Thorac Ann. 2017; 25(9): 594-607.

20. Hang D, Nguyen A, Schaff H. Surgical treatment for hypertrophic cardiomyopathy: a historical perspective. Ann Cardiothorac Surg. 2017; 6(4): 318- 328.

21. Cooper R, Stables R. Non-surgical septal reduction therapy in hypertrophic cardiomyopathy. Heart. 2018; 04(1): 73-83.

22. Crossen K, Jones M, Erikson C. Radiofrequency septal reduction in symptomatic hypertrophic obstructive cardiomyopathy. Heart Rhythm. 2016; 13(9): 1885-1890.

23. Shelke A, Menon R, Kapadiya A, et al. A novel aproach in the use of radiofrequency catheter ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy. Indian Heart Journal. 2016; 68 (5): 618-623.